NASDAQ:GLSI Greenwich LifeSciences Q2 2025 Earnings Report $13.19 -0.08 (-0.60%) Closing price 04:00 PM EasternExtended Trading$12.91 -0.28 (-2.12%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Greenwich LifeSciences EPS ResultsActual EPS-$0.30Consensus EPS -$0.24Beat/MissMissed by -$0.06One Year Ago EPSN/AGreenwich LifeSciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGreenwich LifeSciences Announcement DetailsQuarterQ2 2025Date8/14/2025TimeBefore Market OpensConference Call DateThursday, August 14, 2025Conference Call Time8:00AM ETUpcoming EarningsGreenwich LifeSciences' Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2026 Earnings ReportConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Greenwich LifeSciences Earnings HeadlinesGreenwich LifeSciences (NASDAQ:GLSI) Stock Price Expected to Rise, HC Wainwright Analyst SaysJuly 23 at 1:48 AM | americanbankingnews.comGreenwich LifeSciences Announces UK Regulatory Approval to Expand Phase III FLAMINGO-01 Breast Cancer TrialJuly 22 at 6:31 AM | quiverquant.comQSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, CEO of TradeSmith, is sharing what you can do to protect your wealth before it hits.July 23 at 1:00 AM | TradeSmith (Ad)Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United KingdomJuly 22 at 6:00 AM | globenewswire.comGreenwich LifeSciences Updates FLAMINGO-01 Phase III Trial Design, Enrollment and Financial OutlookJuly 20 at 6:30 AM | quiverquant.comQGreenwich LifeSciences Provides Clinical Updates on FLAMINGO-01July 20 at 6:00 AM | globenewswire.comSee More Greenwich LifeSciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Greenwich LifeSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Greenwich LifeSciences and other key companies, straight to your email. Email Address About Greenwich LifeSciencesGreenwich LifeSciences (NASDAQ:GLSI) (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies. Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States. The company leverages proprietary technologies to identify immune-modulating compounds and works with contract research organizations to support its preclinical and clinical programs. Greenwich LifeSciences pursues strategic collaborations and licensing arrangements to expand its scientific expertise and accelerate the progress of its therapeutic candidates. With a focus on unmet medical needs in oncology and inflammatory disorders, the company aims to bring first-in-class or best-in-class treatments to patients through disciplined clinical development and regulatory strategies.View Greenwich LifeSciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip BattleAlphabet Crushed Earnings, But One Number Spooked the MarketPremium Retail’s Stress Test Is Separating Winners From LosersGE Vernova Just Sent a Mixed AI Signal to InvestorsOtis Took Another Guidance Cut—But the Story Isn't OverPhilip Morris Trimmed Guidance, But Its Growth Story Looks UnshakenD-Wave Quantum or a Quantum ETF: Which Is the Better Bet? Upcoming Earnings Verizon Communications (7/24/2026)ENI (7/24/2026)Phillips 66 (7/24/2026)SLB (7/24/2026)American Express (7/24/2026)HCA Healthcare (7/24/2026)Canadian National Railway (7/24/2026)Baker Hughes (7/26/2026)Nucor (7/27/2026)Cadence Design Systems (7/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
